Anne Horgan joined the Life Sciences Team as an Associate in 2013 and focuses on investments in the biopharmaceutical sector.
Prior to joining Sofinnova, Anne spent five years at Cancer Research Technology Ltd, the technology transfer and development arm of the British charity Cancer Research UK. Her role at CRT encompassed the identification, evaluation, protection, development and commercialisation of intellectual property stemming from academic research funded by Cancer Research UK.
Before moving into the technology transfer and development sector, Anne started her career in the Biotech industry as a senior medicinal chemist at Cambridge Biotechnology Ltd, a Cambridge-based drug discovery start-up company with a core interest in the treatment of pain, inflammation and obesity (later acquired by Proximagen and now part of Upsher Smith). During her five years at Cambridge Biotechnology Ltd, Anne worked on early stage preclinical programmes in both pain and obesity areas.
Anne carried out postdoctoral research at Yale University after her PhD in synthetic organic chemistry from the University of Bristol. She holds a diplôme d’ingénieur from the Institut National des Sciences Appliquées de Rouen, specialising in Chemistry. She is an author on seven peer-reviewed papers and an inventor on eight patent families.